Company intelligence / Profile preview

GC Therapeutics

Cambridge, Massachusetts, United Statesgc-tx.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

GC Therapeutics has developed the TFome™ platform to rapidly generate high-quality iPSC-derived therapeutic cells in a scalable manner. The company claims its technology can produce differentiated human cells in as little as four days via a single-step process—much faster than conventional methods. Their pipeline targets gastrointestinal, neurological, and immunological diseases but remains preclinical with no disclosed clinical results yet.

Therapeutic areas: GastroenterologyImmunologyNeurology
Modalities: Induced pluripotent stem cell (iPSC)-based cell therapiesEngineered "SuperCells" (enhanced iPSC-derived cells)Synthetic biology-driven cellular programming
Industry: Biotech

Beyond the preview

Go deeper on GC Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GC Therapeutics.

Explore the full profile